ACST Acasti Pharma Inc. engages in the research,

ACST Acasti Pharma Inc. engages in the research, development, and commercialization of active pharmaceutical ingredients to treat cardiometabolic disorders. It is developing bioactive ingredients of proprietary novel omega-3 phospholipids through the pharmaceutical development pathway, which includes prescription medical foods, over-the-counter products (OTC), and prescription drugs. The company’s lead prescription drug candidate, CaPre that is in Phase II clinical trial for the prevention and treatment of cardiometabolic disorders, including hypertriglyceridemia, a condition which is characterized by abnormally high levels of triglycerides. Its products also include Onemia, an omega-3 phospholipid concentrate and medical food for chronic cardiometabolic disorders. The company was incorporated in 2002 and is headquartered in Laval, Canada. Acasti Pharma Inc. is a subsidiary of Neptune Technologies and Bioressources Inc.